Apogee Therapeutics Released Interim Data From the Phase 1b Trial of Zumilokibart (APG777) for Mild-to-moderate Asthma Showing Rapid and Durable Suppression of Feno (Key Biomarker of Type 2 Inflammation) Through 16 Weeks for All Patients

Benzinga · 3d ago
  • Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients.
  • Suppression of FeNO through 32 weeks for patients with available follow up.
  • Results reinforce continued development in asthma testing every 3- or 6-month dosing
  • Successful expansion of zumilokibart beyond dermatology confirms its pipeline-in-a-product potential across I&I indications
  • Zumilokibart in atopic dermatitis (AD) advancing in Phase 2 APEX trials with goal of Phase 3 initiation by end of 2026: Part A maintenance (52-week) data readout expected in Q1 2026 with potential to establish best-in-class every 3- or 6-month dosing profile and Part B enrollment completed ahead of schedule and exceeded enrollment target with a total of 347 patients; 16-week induction data readout on track for Q2 2026.
  • Serial innovation in AD advances with APG279 Phase 1b expanded to approximately 80 patients with readout on track for 2H 2026 based on strong enrollment
  • Strong cash position of $913 million with runway into 2H 2028 supports advancement toward potential launch of zumilokibart in 2029